- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06421701
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
May 17, 2024 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
A Clinical Study of Anti-CD19 CAR-NK Cells in the Treatment of Refractory/Relapsed Systemic Lupus Erythematosus
This study is a single-center, open-label, single-arm, dose-escalation trial.
The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Huaxiang Wu, PhD
- Phone Number: 86-13757118395
- Email: wuhx8855@zju.edu.cn
Study Locations
-
-
-
Hangzhou, China, 310016
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- Huaxiang Wu, PhD
- Phone Number: 86-13757118395
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntarily participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up;
- Age range from 18 to 65 years old, regardless of gender;
- Fulfilling the 2019 ACR/EULAR classification criteria of SLE;
- Presence of anti-dsDNA or anti-Sm antibodies and decreased C3 or C4 levels;
- SELENA-SLEDAI≥8;
- Subject has ≥ 1 organ system with BILAG-2004 Class A mobility score or ≥ 2 organ systems with BILAG-2004 Class B mobility score prior to screening;
- Routine treatment is ineffective or the disease relapses after remission. Definition of routine treatment: use more than two drugs, including glucocorticoid (more than 1mg/kg/d), and any two or more of the following immunomodulatory drugs for more than 6 months: cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, leflunomide, tacrolimus, ciclosporin, and biological agents, including rituximab, belizumab, or telitacicept;
- Hemoglobin ≥ 85g/L; white blood cell count ≥ 3 × 10^9/L;neutrophil count ≥ 1.5 × 10^9/L; platelets ≥ 50 × 10^9/L;
- The functions of important organs are basically normal: ALT ≤ 2 × ULN; AST ≤ 2 × ULN; eGFR ≥ 60ml/min/1.73m2; total bilirubin ≤2.0 mg/dL; cardiac function: left ventricular ejection fraction (LVEF) ≥ 50%; non-oxygenated blood oxygen saturation >94%; prothrombin time (PT) ≤ 1.5 × ULN;international standardized ratio (INR) ≤ 1.5 × ULN;
- Females of childbearing potential must use effective contraception during the study. In addition, subjects must not donate eggs during the study and for at least 90 days after the last dose of study treatment;
Exclusion Criteria:
- History of severe allergy or known hypersensitivity to any of the active ingredients of the cell product;
- Pregnant (or lactating) women;
- Severe lupus nephritis (defined as serum creatinine > 2.5 mg/dL or 221 μmol/L), treatment with hemodialysis within 8 weeks prior to screening;
- Other lupus crises, such as active central nervous system lupus, severe hemolytic anemia, severe thrombocytopenic purpura, severe agranulocytosis, severe myocardial damage, severe lupus pneumonia or pulmonary hemorrhage, severe lupus hepatitis, and severe vasculitis within 8 weeks prior to screening;
- Combined with other autoimmune diseases requiring systemic therapy;
- Clinically significant central nervous system diseases or pathological changes not caused by lupus prior to screening, including but not limited to: cerebrovascular accident, aneurysm, epilepsy, convulsions/convulsions, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis;
- Abnormal test results for hepatitis B or C indicate the presence of an active or chronic infection, including positive HBsAg or positive HBcAb with HBV DNA levels exceeding the normal upper limit,positive hepatitis C antibody and detectable HCV RNA;positive serology for human immunodeficiency virus (HIV) or a known history of HIV infection;
- Cytomegalovirus DNA levels and EB (Epstein-Barr) virus DNA levels in the peripheral blood exceeding the normal upper limits;
- Active or latent tuberculosis;
- Presence of uncontrollable bacterial, fungal, viral or other infections, requiring antibiotic therapy;
- Acquired and congenital immunodeficiency diseases;
- IgA deficiency;
- Other uncontrolled diseases: acute or chronic diseases that are clinically unstable or have not been effectively controlled and are not related to SLE;
- History of malignant diseases such as malignant tumors, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, superficial bladder cancer, breast cancer;
- Any active skin disease that may interfere with the study assessment of SLE, including but not limited to psoriasis, dermatomyositis, systemic sclerosis, non-LE cutaneous lupus manifestations (eg, cutaneous vascular disease, periungual telangiectasia, fingertip sclerosis, rheumatoid nodules, erythema multiforme, leg ulcers) or drug-induced lupus;
- Prior treatment with cell therapy or any prior gene therapy product;
- Contraindication to cyclophosphamide in combination with fludarabine;
- Prior CD19-targeted therapy;
- Received live vaccine treatment within 4 weeks prior to screening;
- Subjects who have undergone major surgery within 8 weeks prior to screening, or who are scheduled to have surgery during the trial;
- Have received B-cell targeted therapy within 4 weeks prior to screening;
- Have received immunosuppressants within 1 week prior to screening;
- Have received plasmapheresis or intravenous immunoglobulin within 3 months prior to screening;
- Have participated in other clinical studies within 3 months prior to screening;
- History of vital organ transplantation (eg, heart, lung, kidney, liver) or hematopoietic stem cell/or bone marrow transplantation;
- Situations in which investigators consider it inappropriate to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: anti-CD19 CAR-NK cells
To evaluate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.
All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by anti-CD19 CAR-NK cells infusion on Day 0, 7, and 14.
|
Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (500mg/m2 per day) on day -5, -4, and -3.
Doses of 2×10^6/kg, 3×10^6/kg, 4×10^6/kg anti-CD19 CAR-NK cells will be infused in each group on Day 0, 7, and 14 using the "3 + 3" dose-escalation strategy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of subjects with DLT
Time Frame: Within 28 days after anti-CD19 CAR-NK cells infusion
|
DLT definition is dose-limiting toxicity.
|
Within 28 days after anti-CD19 CAR-NK cells infusion
|
The proportion of subjects with adverse events
Time Frame: 12 months
|
Incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signs as assessed by CTCAE v5.0.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with Systemic Lupus Erythematosus Responder Index-4 (SRI-4) response
Time Frame: 4, 8, 12, 16, 20, 24, 36 and 52 weeks after infusion
|
Proportion of patients with SRI-4 response: including SELENA-SLEDAI ≥4-Point improvement, BILAG 2004 with no new A domain score AND no more than 1 new B domain scores, PGA with No worsening (<0.3-point increase).
|
4, 8, 12, 16, 20, 24, 36 and 52 weeks after infusion
|
Proportion of participants achieving definition of remission in SLE (DORIS) remission
Time Frame: 4, 8, 12, 16, 20, 24, 36 and 52 weeks after infusion
|
The Definition of Remission in SLE (DORIS) is a standardized criterion to clearly define what constitutes remission in patients with systemic lupus erythematosus.
|
4, 8, 12, 16, 20, 24, 36 and 52 weeks after infusion
|
Proportion of participants achieving Lupus Low Disease Activity State (LLDAS)
Time Frame: 4, 8, 12, 16, 20, 24, 36 and 52 weeks after infusion
|
The Lupus Low Disease Activity State (LLDAS) is a clinical treatment target designed for patients with systemic lupus erythematosus.
It represents a state where the disease activity is kept at a low level, aiming to minimize symptoms and prevent long-term damage caused by the disease.
|
4, 8, 12, 16, 20, 24, 36 and 52 weeks after infusion
|
Changes in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2000) score from baseline
Time Frame: Within 12 months after anti-CD19 CAR-NK cell infusion
|
Assessment of SLEDAI-2000 from baseline administration at various timepoints up to month 12 follow up visit.
|
Within 12 months after anti-CD19 CAR-NK cell infusion
|
Changes in the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score from baseline
Time Frame: Within 12 months after anti-CD19 CAR-NK cell infusion
|
Assessment of SELENA-SLEDAI from baseline administration at various timepoints up to month 12 follow up visit.
|
Within 12 months after anti-CD19 CAR-NK cell infusion
|
Changes in the British Isles Lupus Assessment Group 2004 index (BILAG-2004) from baseline
Time Frame: Within 12 months after anti-CD19 CAR-NK cell infusion
|
Assessment of BILAG-2004 from baseline administration at various timepoints up to month 12 follow up visit.
|
Within 12 months after anti-CD19 CAR-NK cell infusion
|
Changes in the Physician Global Assessment (PGA) from baseline
Time Frame: Within 12 months after anti-CD19 CAR-NK cell infusion
|
Assessment of PGA from baseline administration at various timepoints up to month 12 follow up visit.
|
Within 12 months after anti-CD19 CAR-NK cell infusion
|
Change in proteinuria measured by 24h proteinuria or urine protein creatinine ratio (UPCR) from baseline
Time Frame: Within 12 months after anti-CD19 CAR-NK cell infusion
|
Assessment of 24h proteinuria or urine protein creatinine ratio (UPCR) from baseline administration at various timepoints up to month 12 follow up visit.
|
Within 12 months after anti-CD19 CAR-NK cell infusion
|
Changes in level of anti-nuclear antibody (ANA) in peripheral blood from baseline
Time Frame: Within 12 months after anti-CD19 CAR-NK cell infusion
|
Assessment of ANA from baseline administration at various timepoints up to month 12 follow up visit.
|
Within 12 months after anti-CD19 CAR-NK cell infusion
|
Changes in levels of complement C3 and C4 in peripheral blood from baseline
Time Frame: Within 12 months after anti-CD19 CAR-NK cell infusion
|
Assessment of C3 and C4 from baseline administration at various timepoints up to month 12 follow up visit.
|
Within 12 months after anti-CD19 CAR-NK cell infusion
|
CMAX of anti-CD19 CAR-NK cells
Time Frame: 3 months
|
CMAX is defined as the highest concentration of anti-CD19 CAR-NK cell expansion in the peripheral blood.
|
3 months
|
TMAX of anti-CD19 CAR-NK cells
Time Frame: 3 months
|
TMAX is defined as the time to reach the highest concentration of anti-CD19 CAR-NK cell expansion in the peripheral blood.
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Huaxiang Wu, Second Affiliated Hospital, School of Medicine, Zhejiang University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
May 31, 2026
Study Registration Dates
First Submitted
May 13, 2024
First Submitted That Met QC Criteria
May 17, 2024
First Posted (Actual)
May 20, 2024
Study Record Updates
Last Update Posted (Actual)
May 20, 2024
Last Update Submitted That Met QC Criteria
May 17, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-0530
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...CompletedSystemic Lupus Erythematosus | Cutaneous Lupus ErythematosusSpain, Bulgaria, Germany, Moldova, Republic of, North Macedonia, Ukraine
Clinical Trials on anti-CD19 CAR-NK cells
-
Allife Medical Science and Technology Co., Ltd.UnknownRefractory B-Cell Lymphoma
-
Allife Medical Science and Technology Co., Ltd.Peking University Cancer Hospital & InstituteUnknownRefractory B-Cell Lymphoma
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownFollicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | B-cell Prolymphocytic LeukemiaChina
-
Xuzhou Medical UniversityRecruitingB-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic LeukemiaChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingB-cell Non Hodgkin LymphomaChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingB-cell Non Hodgkin LymphomaChina
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
YANRU WANGRui Therapeutics Co., LtdRecruiting
-
Changhai HospitalNanjing Enricnk Biotech Co., LtdRecruitingDiffuse Large B Cell LymphomaChina
-
Changzhou No.2 People's HospitalRui Therapeutics Co., LtdNot yet recruitingThrombocytopenia Alloimmune